Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 371.40M | -527.10M | 720.00M | -341.90M | 317.80M |
| Total Depreciation and Amortization | 41.10M | 40.90M | 42.50M | 44.20M | 40.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -452.20M | 762.80M | -851.70M | 521.00M | -319.00M |
| Change in Net Operating Assets | 138.40M | -168.50M | 254.10M | -102.40M | 77.10M |
| Cash from Operations | 98.70M | 108.10M | 164.90M | 120.90M | 116.50M |
| Capital Expenditure | -32.00M | -30.00M | -45.80M | -31.70M | -45.70M |
| Sale of Property, Plant, and Equipment | -100.00K | 100.00K | 0.00 | 0.00 | 100.00K |
| Cash Acquisitions | 1.10M | -- | 0.00 | -1.80M | -216.70M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -35.70M | -63.30M | 11.60M | -9.50M | 146.90M |
| Cash from Investing | -66.70M | -93.20M | -34.20M | -43.00M | -115.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -200.00K | -100.00K | -200.00K | 0.00 | -200.00K |
| Issuance of Common Stock | 4.20M | 3.40M | 3.90M | 3.40M | 4.20M |
| Repurchase of Common Stock | -31.60M | -47.80M | -400.00K | -55.90M | -140.30M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 500.00K | -- | -- | -- |
| Cash from Financing | -27.60M | -44.00M | 3.30M | -52.50M | -136.30M |
| Foreign Exchange rate Adjustments | 5.40M | 5.90M | 0.00 | 1.10M | -16.20M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.80M | -23.20M | 134.00M | 26.50M | -151.40M |